MASI:NGS-Masimo Corporation (USD)

EQUITY | Medical Devices | Nasdaq Global Select

Last Closing

USD 167.51

Change

-2.01 (-1.19)%

Market Cap

USD 3.07B

Volume

0.33M

Analyst Target

USD 251.80
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Masimo Corp is a medical technology company. The Company develops, manufactures, and markets noninvasive monitoring technologies. Its product includes noninvasive blood constituent and brain and breath monitoring.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-23 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-0.50 (-0.62%)

USD 30.74B
PODD Insulet Corporation

-3.24 (-1.22%)

USD 19.01B
BRKR Bruker Corporation

+0.39 (+0.68%)

USD 9.04B
PRCT Procept Biorobotics Corp

-0.02 (-0.02%)

USD 4.83B
NVCR Novocure Ltd

-0.31 (-1.01%)

USD 3.61B
NARI Inari Medical Inc

-2.21 (-3.99%)

USD 3.25B
LIVN LivaNova PLC

-0.60 (-1.26%)

USD 2.83B
IRTC iRhythm Technologies Inc

-1.73 (-1.91%)

USD 2.67B
QDEL Quidel Corporation

-0.18 (-0.40%)

USD 2.57B
TMDX TransMedics Group Inc

+0.95 (+1.54%)

USD 2.07B

ETFs Containing MASI

EDOC:AU BetaShares Digital Health.. 4.80 % 0.00 %

+0.23 (+0%)

N/A
EDOC:LSE Global X Telemedicine & D.. 4.68 % 0.00 %

-0.06 (0%)

USD 2.08M
EDOG:LSE Global X Telemedicine & D.. 4.68 % 0.00 %

+0.01 (+0%)

USD 0.42M
DDOC:F Global X Telemedicine & D.. 4.59 % 0.00 %

+0.25 (+0%)

USD 4.62M
FDHT 3.90 % 0.00 %

N/A

N/A
XHE SPDR® S&P Health Care Eq.. 2.79 % 0.35 %

-0.26 (0%)

USD 0.21B
HTEC Robo Global® Healthcare .. 1.84 % 0.00 %

+0.09 (+0%)

USD 0.05B
EQWM Invesco S&P MidCap Qualit.. 0.00 % 0.25 %

N/A

N/A
PXMG 0.00 % 0.39 %

N/A

N/A
YXM.A:CA 0.00 % 1.49 %

N/A

N/A
YXM.D:CA 0.00 % 1.53 %

N/A

N/A
SIXL 6 Meridian Low Beta Equit.. 0.00 % 0.00 %

-0.05 (0%)

USD 0.19B
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

-0.10 (0%)

USD 0.04B
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.00 %

-0.04 (0%)

USD 5.39M

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 42.91% 84% B 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.91% 84% B 85% B
Trailing 12 Months  
Capital Gain 41.92% 82% B 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.92% 82% B 84% B
Trailing 5 Years  
Capital Gain 5.09% 79% B- 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.09% 79% B- 48% F
Average Annual (5 Year Horizon)  
Capital Gain -4.81% 34% F 27% F
Dividend Return -4.81% 34% F 26% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 35.87% 79% B- 53% F
Risk Adjusted Return -13.42% 34% F 26% F
Market Capitalization 3.07B 98% N/A 92% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 29.90 18% 10%
Price/Book Ratio 6.45 27% 20%
Price / Cash Flow Ratio 100.22 5% 3%
Price/Free Cash Flow Ratio 45.73 7% 9%
Management Effectiveness  
Return on Equity 5.74% 90% 68%
Return on Invested Capital 5.69% 82% 68%
Return on Assets 2.66% 88% 76%
Debt to Equity Ratio 63.87% 41% 35%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.